Several antigens (including CD33, CD123, CLL1, CD244, TIM3 and CD7), known to be overexpressed on AML leukaemic stem cells (LSCs), have been extensively evaluated in preclinical models [3] and early clinical settings [4]. The gene discussed is CD33; the disease is acute myeloid leukemia.